Page 1 | Search Results | Hematology, ASH Education Program

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Management of multiple myeloma in the newly diagnosed patient

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 498–507.

https://doi.org/10.1182/asheducation-2017.1.498

Published: 2017

Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.

https://doi.org/10.1182/asheducation-2016.1.485

Published: 2016

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Maintenance therapy for multiple myeloma in the era of novel agents

Thierry Facon

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 279–285.

https://doi.org/10.1182/asheducation-2015.1.279

Published: 2015

Journal Articles

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 255–261.

https://doi.org/10.1182/asheducation-2014.1.255

Published: 2014

Journal Articles

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

S. Vincent Rajkumar

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 354–361.

https://doi.org/10.1182/asheducation.V2012.1.354.3798330

Published: 2012

Journal Articles

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Emma Scott, Donna Reece

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 205–207.

https://doi.org/10.1182/asheducation-2011.1.205

Published: 2011

Journal Articles

Stem Cell Transplantation for Multiple Myeloma: Current and Future Status

Sergio Giralt

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 191–196.

https://doi.org/10.1182/asheducation-2011.1.191

Published: 2011

Journal Articles

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

Adam D. Cohen, Raymond L. Comenzo

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 287–294.

https://doi.org/10.1182/asheducation-2010.1.287

Published: 2010

Journal Articles

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing

Antonio Palumbo, Francesca Gay

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 566–577.

https://doi.org/10.1182/asheducation-2009.1.566

Published: 2009

Journal Articles

Induction Therapy in Multiple Myeloma

Jean-Luc Harousseau

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 306–312.

https://doi.org/10.1182/asheducation-2008.1.306

Published: 2008

Journal Articles

Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation

Robert Z. Orlowski

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 338–347.

https://doi.org/10.1182/asheducation-2006.1.338

Published: 2006

Journal Articles

Amyloidosis and Waldenström’s Macroglobulinemia

Morie A. Gertz, Giampaolo Merlini, Steven P. Treon

Hematology Am Soc Hematol Educ Program (2004) 2004 (1): 257–282.

https://doi.org/10.1182/asheducation-2004.1.257

Published: 2004

Journal Articles

Advances in Biology and Therapy of Multiple Myeloma

Sophie Barillé-Nion, Bart Barlogie, Régis Bataille, P. Leif Bergsagel, Joshua Epstein, Robert G. Fenton, Joth Jacobson, W. Michael Kuehl, John Shaughnessy, Guido Tricot

Hematology Am Soc Hematol Educ Program (2003) 2003 (1): 248–278.

https://doi.org/10.1182/asheducation-2003.1.248

Published: 2003

NARROW

Fixed duration vs continuous therapy in multiple myeloma

Management of multiple myeloma in the newly diagnosed patient

Myeloma: management of the newly diagnosed high-risk patient

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Maintenance therapy for multiple myeloma in the era of novel agents

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Stem Cell Transplantation for Multiple Myeloma: Current and Future Status

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing

Induction Therapy in Multiple Myeloma

Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation

Amyloidosis and Waldenström’s Macroglobulinemia

Advances in Biology and Therapy of Multiple Myeloma

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only